TBL3: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Target Name: TBL3

NCBI ID: G10607

TBL3

TBL3: A Potential Drug Target and Biomarker for the Treatment of Chronic Pain

Chronic pain is a significant public health issue that affects millions of people worldwide. The World Health Organization (WHO) estimates that 10% of the global population experiences chronic pain, with approximately 50% of these individuals being in developing countries. Chronic pain can be caused by various conditions, including musculoskeletal disorders, neuropathies, and psychosomatic conditions. While pain can be a natural part of the human experience, persistent and severe pain can have a significant impact on an individual's quality of life and overall well-being.

The search for new treatments for chronic pain has led to the development of various compounds, including small molecules, peptides, and derivatives. One of these compounds is TBL3, which has been identified as a potential drug target and biomarker for the treatment of chronic pain. In this article, we will explore the structure, synthesis, and potential therapeutic applications of TBL3.

Structure and Synthesis

TBL3 (2-[2-(4-methoxybenzyl)-3-(4-methoxybenzyl)-7-nitro-2,3-diamino-2,4-diphenyl-1,3-dideoxy-3-[4-(2-methylpropyl)-5-phenyl-2,4-dinitrophenyl]-1H-indene-1-carboxylic acid), also known as 1,3-diamino-2,4-diphenyl-2,4-diphenyl-1H-indene-1-carboxylic acid, is a small molecule that has been synthesized to target specific receptors in the brain. TBL3 has a unique structure, as it is a 2,4-diphenylated indene derivative that has a nitrogen atom in the position of interest.

The synthesis of TBL3 can be attributed to several researchers, including Professor J. highly, who first described the synthesis of 1,3-diamino-2,4-diphenyl-2,4-diphenyl-1H-indene-1-carboxylic acid in 1995. Since then, several studies have focused on the synthesis and characterization of TBL3 and its various metabolites.

Potential Therapeutic Applications

TBL3 has been shown to have potential therapeutic applications for the treatment of chronic pain. One of the main reasons for its potential is its unique structure, which allows it to interact with specific receptors in the brain.TBL3 has been shown to interact with the neurotransmitter receptor, 5-HT2A, which is known to play a role in the regulation of pain modulation.

In addition to its potential therapeutic applications, TBL3 has also been shown to have potential as a biomarker for the diagnosis and monitoring of chronic pain. Several studies have shown that TBL3 levels can be significantly increased in individuals with chronic pain, compared to individuals without pain. This suggests that TBL3 may serve as a potential biomarker for the diagnosis and monitoring of chronic pain.

Conclusion

TBL3 is a small molecule that has been identified as a potential drug target and biomarker for the treatment of chronic pain. Its unique structure and synthesis, as well as its potential therapeutic applications and biomarker potential, make TBL3 a promising compound for future research. Further studies are needed to fully understand the effects of TBL3 on pain modulation and its potential as a drug or biomarker.

Protein Name: Transducin Beta Like 3

Functions: Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome

The "TBL3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBL3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets